Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2004;110:3121-3128
Published online before print November 1, 2004, doi: 10.1161/01.CIR.0000147181.65298.4D
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
110/19/3121    most recent
01.CIR.0000147181.65298.4Dv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sharma, U. C.
Right arrow Articles by Pinto, Y. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sharma, U. C.
Right arrow Articles by Pinto, Y. M.
Related Collections
Right arrow Cardio-renal physiology/pathophysiology
Right arrow Remodeling
Right arrow Animal models of human disease
Right arrow Hypertrophy
Right arrow Physiological and pathological control of gene expression

(Circulation. 2004;110:3121-3128.)
© 2004 American Heart Association, Inc.


Molecular Cardiology

Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac Dysfunction

Umesh C. Sharma, MB BS, MSc; Saraswati Pokharel, MB BS; Thomas J. van Brakel, MD; Jop H. van Berlo, MD; Jack P.M. Cleutjens, PhD; Blanche Schroen, MSc; Sabine André, PhD; Harry J.G.M. Crijns, MD, PhD; Hans -J. Gabius, PhD; Jos Maessen, MD, PhD; Yigal M. Pinto, MD, PhD

From the Experimental and Molecular Cardiology Laboratory, Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM) (U.C.S., S.P., J.H.v.B., B.S., H.J.G.M.C., Y.M.P.), the Department of Cardiothoracic Surgery, University Hospital Maastricht (U.C.S., T.J.v.B., J.M.), and the Department of Pathology, CARIM, University of Maastricht (J.P.M.C.), Maastricht, the Netherlands; and the Institute of Physiological Chemistry, Faculty of Veterinary Medicine, Ludwig-Maximilians University, Munich, Germany (S.A., H.-J.G.).

Correspondence to Yigal M. Pinto, MD, PhD, Experimental and Molecular Cardiology, Department of Cardiology, 6202 AZ Maastricht, The Netherlands. E-mail y.pinto{at}carim.unimaas.nl

Received April 14, 2004; revision received August 18, 2004; accepted August 23, 2004.

Background— Inflammatory mechanisms have been proposed to be important in heart failure (HF), and cytokines have been implicated to add to the progression of HF. However, it is unclear whether such mechanisms are already activated when hypertrophied hearts still appear well-compensated and whether such early mechanisms contribute to the development of HF.

Methods and Results— In a comprehensive microarray study, galectin-3 emerged as the most robustly overexpressed gene in failing versus functionally compensated hearts from homozygous transgenic TGRmRen2-27 (Ren-2) rats. Myocardial biopsies obtained at an early stage of hypertrophy before apparent HF showed that expression of galectin-3 was increased specifically in the rats that later rapidly developed HF. Galectin-3 colocalized with activated myocardial macrophages. We found galectin-3-binding sites in rat cardiac fibroblasts and the extracellular matrix. Recombinant galectin-3 induced cardiac fibroblast proliferation, collagen production, and cyclin D1 expression. A 4-week continuous infusion of low-dose galectin-3 into the pericardial sac of healthy Sprague-Dawley rats led to left ventricular dysfunction, with a 3-fold differential increase of collagen I over collagen III. Myocardial galectin-3 expression was increased in aortic stenosis patients with depressed ejection fraction.

Conclusions— This study shows that an early increase in galectin-3 expression identifies failure-prone hypertrophied hearts. Galectin-3, a macrophage-derived mediator, induces cardiac fibroblast proliferation, collagen deposition, and ventricular dysfunction. This implies that HF therapy aimed at inflammatory responses may need to be targeted at the early stages of HF and probably needs to antagonize multiple inflammatory mediators, including galectin-3.


Key Words: angiotensin • collagen • fibroblasts • heart failure




This article has been cited by other articles:


Home page
Eur J Heart FailHome page
R. A. de Boer, A. A. Voors, P. Muntendam, W. H. van Gilst, and D. J. van Veldhuisen
Galectin-3: a novel mediator of heart failure development and progression
Eur J Heart Fail, September 1, 2009; 11(9): 811 - 817.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
H. R. Zandbergen, U. C. Sharma, S. Gupta, J. W. H. Verjans, S. van den Borne, S. Pokharel, T. van Brakel, A. Duijvestijn, N. van Rooijen, J. G. Maessen, et al.
Macrophage Depletion in Hypertensive Rats Accelerates Development of Cardiomyopathy
Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2009; 14(1): 68 - 75.
[Abstract] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y.-H. Liu, M. D'Ambrosio, T.-d. Liao, H. Peng, N.-E. Rhaleb, U. Sharma, S. Andre, H.-J. Gabius, and O. A. Carretero
N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin
Am J Physiol Heart Circ Physiol, February 1, 2009; 296(2): H404 - H412.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
U. Sharma, N.-E. Rhaleb, S. Pokharel, P. Harding, S. Rasoul, H. Peng, and O. A. Carretero
Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage
Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1226 - H1232.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. C. MacKinnon, S. L. Farnworth, P. S. Hodkinson, N. C. Henderson, K. M. Atkinson, H. Leffler, U. J. Nilsson, C. Haslett, S. J. Forbes, and T. Sethi
Regulation of Alternative Macrophage Activation by Galectin-3
J. Immunol., February 15, 2008; 180(4): 2650 - 2658.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
N. C. Henderson, A. C. Mackinnon, S. L. Farnworth, T. Kipari, C. Haslett, J. P. Iredale, F.-T. Liu, J. Hughes, and T. Sethi
Galectin-3 Expression and Secretion Links Macrophages to the Promotion of Renal Fibrosis
Am. J. Pathol., February 1, 2008; 172(2): 288 - 298.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
S. S. Palaniyandi, Y. Nagai, K. Watanabe, M. Ma, P. T. Veeraveedu, P. Prakash, F. A. Kamal, Y. Abe, K. Yamaguchi, H. Tachikawa, et al.
Chymase Inhibition Reduces the Progression to Heart Failure After Autoimmune Myocarditis in Rats
Experimental Biology and Medicine, October 1, 2007; 232(9): 1213 - 1221.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
K. Reifenberg, H.-A. Lehr, M. Torzewski, G. Steige, E. Wiese, I. Kupper, C. Becker, S. Ott, P. Nusser, K.-I. Yamamura, et al.
Interferon-{gamma} Induces Chronic Active Myocarditis and Cardiomyopathy in Transgenic Mice
Am. J. Pathol., August 1, 2007; 171(2): 463 - 472.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
W.H. Wilson Tang, G. S. Francis, D. A. Morrow, L. K. Newby, C. P. Cannon, R. L. Jesse, A. B. Storrow, R. H. Christenson, COMMITTEE MEMBERS, R. H. Christenson, et al.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure
Circulation, July 31, 2007; 116(5): e99 - e109.
[Full Text] [PDF]


Home page
JEMHome page
B. Schroen, J. J. Leenders, A. van Erk, A. T. Bertrand, M. van Loon, R. E. van Leeuwen, N. Kubben, R. F. Duisters, M. W. Schellings, B. J. Janssen, et al.
Lysosomal integral membrane protein 2 is a novel component of the cardiac intercalated disc and vital for load-induced cardiac myocyte hypertrophy
J. Exp. Med., May 14, 2007; 204(5): 1227 - 1235.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
C. Pilette, B. Colinet, R. Kiss, S. Andre, H. Kaltner, H-J. Gabius, M. Delos, J-P. Vaerman, M. Decramer, and Y. Sibille
Increased galectin-3 expression and intra-epithelial neutrophils in small airways in severe COPD
Eur. Respir. J., May 1, 2007; 29(5): 914 - 922.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. R. van Kimmenade, J. L. Januzzi Jr, P. T. Ellinor, U. C. Sharma, J. A. Bakker, A. F. Low, A. Martinez, H. J. Crijns, C. A. MacRae, P. P. Menheere, et al.
Utility of Amino-Terminal Pro-Brain Natriuretic Peptide, Galectin-3, and Apelin for the Evaluation of Patients With Acute Heart Failure
J. Am. Coll. Cardiol., September 19, 2006; 48(6): 1217 - 1224.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. W.M. Schellings, M. Baumann, R. E.W. van Leeuwen, R. F.J.J. Duisters, S. H.P. Janssen, B. Schroen, C. J. Peutz-Kootstra, S. Heymans, and Y. M. Pinto
Imatinib Attenuates End-Organ Damage in Hypertensive Homozygous TGR(mRen2)27 Rats
Hypertension, March 1, 2006; 47(3): 467 - 474.
[Abstract] [Full Text] [PDF]